184 related articles for article (PubMed ID: 27437007)
1. Lamotrigine Augmentation Versus Placebo in Serotonin Reuptake Inhibitors-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial.
Khalkhali M; Aram S; Zarrabi H; Kafie M; Heidarzadeh A
Iran J Psychiatry; 2016 Apr; 11(2):104-14. PubMed ID: 27437007
[TBL] [Abstract][Full Text] [Related]
2. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Bruno A; Micò U; Pandolfo G; Mallamace D; Abenavoli E; Di Nardo F; D'Arrigo C; Spina E; Zoccali RA; Muscatello MR
J Psychopharmacol; 2012 Nov; 26(11):1456-62. PubMed ID: 22351381
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
[TBL] [Abstract][Full Text] [Related]
5. Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial.
Ghobadian A; Mokhtari S; Shariati B; Kamalzadeh L; Shati M; Eftekhar Ardebili M; Yarahmadi M; Shalbafan M
BMC Pharmacol Toxicol; 2022 Sep; 23(1):73. PubMed ID: 36167636
[TBL] [Abstract][Full Text] [Related]
6. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study.
Emamzadehfard S; Kamaloo A; Paydary K; Ahmadipour A; Zeinoddini A; Ghaleiha A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
Psychiatry Clin Neurosci; 2016 Aug; 70(8):332-41. PubMed ID: 27106362
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
Mowla A; Boostani S; Dastgheib SA
J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
[TBL] [Abstract][Full Text] [Related]
8. L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
Nematizadeh M; Ghorbanzadeh H; Moghaddam HS; Shalbafan M; Boroon M; Keshavarz-Akhlaghi AA; Akhondzadeh S
Psychiatry Clin Neurosci; 2023 Sep; 77(9):478-485. PubMed ID: 37169515
[TBL] [Abstract][Full Text] [Related]
9. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
[TBL] [Abstract][Full Text] [Related]
10. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Aboujaoude E; Gamel NN
J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
[TBL] [Abstract][Full Text] [Related]
11. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
Tzavellas E; Karaiskos D; Ilias I; Liappas I; Paparrigopoulos T
Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
Ak M; Bulut SD; Bozkurt A; Ozsahin A
Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
[TBL] [Abstract][Full Text] [Related]
13. Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disorder.
Arrojo-Romero M; Tajes Alonso M; de Leon J
Case Rep Psychiatry; 2013; 2013():612459. PubMed ID: 23936714
[TBL] [Abstract][Full Text] [Related]
14. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
Askari N; Moin M; Sanati M; Tajdini M; Hosseini SM; Modabbernia A; Najand B; Salimi S; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
CNS Drugs; 2012 Oct; 26(10):883-92. PubMed ID: 22873680
[TBL] [Abstract][Full Text] [Related]
15. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
[TBL] [Abstract][Full Text] [Related]
16. Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial.
Afshar H; Akuchekian S; Mahaky B; Zarean E
J Res Med Sci; 2014 Oct; 19(10):976-81. PubMed ID: 25538783
[TBL] [Abstract][Full Text] [Related]
17. Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial.
Shokrani M; Askari S; Eissazade N; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
BMC Psychiatry; 2023 Sep; 23(1):686. PubMed ID: 37735631
[TBL] [Abstract][Full Text] [Related]
18. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis.
Maiti R; Mishra A; Srinivasan A; Mishra BR
Acta Psychiatr Scand; 2023 Jul; 148(1):19-31. PubMed ID: 37177823
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
